GovBidAlerts
OpenSolicitationFederal

Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

Department of Defense · Defense Health Agency (dha)

Due Closes in 12 daysRef. HT9402-27-Q-9102

At a glance

What

The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents.

Industry: Pharmaceutical Preparation Manufacturing (NAICS 325412)

Who can bid
Any business — no set-aside listed
Where
San Antonio, TX
Key dates
  • Posted: Nov 12, 2026
  • Deadline: Mon, Nov 30, 2026 · 12:00 PM CST (closes in 12 days)
How to respond

Stephanie Erpelding · stephanie.j.erpelding.civ@health.mil

Submit per the instructions on SAM.gov ↗

Description

The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF).
Read more ↓
Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following February 2027 newly approved drugs will be reviewed: Atebrioz – Skeletal Muscle Relaxants and Combinations – Subclass: NA Emcitate – Thyroid and Antithyroid Agents – Subclass: NA Hibsago – Hepatitis B Agents – Subclass: NA Juvmo – Parkinsons Agents – Subclass: NA Zegfrovy – Lung Cancer – Subclass: EGFR+ NSCLC The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-27-Q-9102. Pre-quotation teleconference is on November 17, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.

Documents (9)

All notice detailsShow ↓
Solicitation number
HT9402-27-Q-9102
Notice type
Solicitation
Product/service code (PSC)
6505
Department
Department of Defense
Sub-agency
Defense Health Agency (dha)
Contracting office
DEFENSE HEALTH AGENCY
Office location
AURORA, CO, 80011
Place of performance
San Antonio, Texas, 78230, UNITED STATES
Archive date
Mar 12, 2027

Contacts